New York’s inclusion of anxiety as a qualifying condition for medical cannabis creates a significant mismatch between regulatory approval and clinical evidence. This expansion affects how clinicians counsel patients and manage expectations when anxiety patients seek cannabis recommendations.
New York has added anxiety disorders to its medical cannabis program’s qualifying conditions list, despite limited robust clinical evidence supporting cannabis efficacy for anxiety. While some cannabis constituents like CBD show preliminary anxiolytic effects in small studies, THC can paradoxically increase anxiety in many patients. The regulatory decision appears driven by patient demand and political considerations rather than established clinical evidence. Current research suggests cannabis effects on anxiety are highly variable, dose-dependent, and influenced by individual factors including genetics and prior cannabis exposure.
“I frequently see patients convinced cannabis will treat their anxiety, but the reality is we’re essentially conducting individual experiments with each patient. The regulatory cart is clearly ahead of the evidence horse here.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
I notice that the article content you provided appears to be incomplete HTML formatting and metadata, but doesn’t contain the actual article text or content. The text cuts off mid-sentence and only shows styling elements, tags, and partial formatting code.
Without the actual article content, I cannot generate meaningful FAQs. Could you please provide the complete article text so I can create relevant questions and answers based on the actual content?